BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2020 3:43:52 AM | Browse: 1283 | Download: 3203
Publication Name World Journal of Clinical Cases
Manuscript ID 55298
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
Manuscript Source Unsolicited Manuscript
All Author List Zhu-Zeng Yin, Zhi-Ming Zhao, Wen-Bo Tang, Nan Jiang, Ke-Di Zhang, Yu-Yao Song, Yang Wang, Cheng-Gang Li, Yuan-Xing Gao and Rong Liu
ORCID
Author(s) ORCID Number
Zhu-Zeng Yin http://orcid.org/0000-0002-3483-1844
Zhi-Ming Zhao http://orcid.org/0000-0003-2374-0856
Wen-Bo Tang http://orcid.org/0000-0002-8418-2045
Nan Jiang http://orcid.org/0000-0003-4077-1785
Ke-Di Zhang http://orcid.org/0000-0003-2993-4997
Yu-Yao Song http://orcid.org/0000-0002-9048-0591
Yang Wang http://orcid.org/0000-0002-1794-9111
Cheng-Gang Li http://orcid.org/0000-0001-7990-1300
Yuan-Xing Gao http://orcid.org/0000-0001-6094-9793
Rong Liu http://orcid.org/0000-0001-5170-6474
Funding Agency and Grant Number
Funding Agency Grant Number
China Postdoctoral Science Foundation 2015M582853
Corresponding Author Rong Liu, MD, PhD, Professor, The Second Department of Hepatopancreatobiliary Surgery, The First Medical Center, Chinese People’s Liberation Army General Hospital, Fuxing Road, No. 28, Beijing 100853, China. liurong301@126.com
Key Words Nab-paclitaxel; Gemcitabine; Pancreatic ductal adenocarcinoma; Surgery; Adjuvant; Resectable
Core Tip Nab-paclitaxel plus gemcitabine (AG) has resulted in better survival and tumor response rates for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone. However, its role in adjuvant therapy for resected PDAC remains unclear. We retrospectively reviewed our PDAC database for patients with primary resectable PDAC who treated with AG or GEM alone as postoperative adjuvant chemotherapy between January 2013 and December 2016. Our results suggested that AG significantly improved disease-free survival and overall survival of patients with resected PDAC. AG may be potential option for postoperative adjuvant chemotherapy of resectable PDAC.
Publish Date 2020-07-07 03:43
Citation Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786
URL https://www.wjgnet.com/2307-8960/full/v8/i13/2778.htm
DOI https://dx.doi.org/10.12998/wjcc.v8.i13.2778
Full Article (PDF) WJCC-8-2778.pdf
Full Article (Word) WJCC-8-2778.docx